Infinity Pharmaceuticals to Participate in Three Investor Conferences This Month
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) announced that CEO Adelene Perkins will present virtually at three investor conferences from January 7-14, 2021. The conferences include the 39th Annual J.P. Morgan Healthcare Conference on January 14, LifeSci Advisors Corporate Access Event from January 7-13, and H.C. Wainwright BioConnect 2021 Conference from January 11-14. One-on-one meetings will also be available. Infinity is actively developing eganelisib, an immuno-oncology candidate targeting cancer treatment through various ongoing clinical studies.
- None.
- None.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) today announced that CEO Adelene Perkins is scheduled to present virtually at three investor conferences this month. The Infinity leadership team also will be available for one-on-one meetings during the investor conferences on January 7-8 and 11-14, 2021.
Details for all three investor conferences are as follows:
39th Annual J.P. Morgan Healthcare Conference - Corporate Presentation
Date: |
January 14, 2021 |
|
Time: |
2:00 p.m. ET |
|
Webcast: |
Audio-only Link to Webcast Here |
2021 LifeSci Advisors - Corporate Access Event
Date: |
January 7-13, 2021 |
|
Time: |
Management available for 1x1 meetings |
H.C. Wainwright BioConnect 2021 Conference - Corporate Presentation
Date: |
January 11-14, 2021 |
The session time is on-demand, beginning Monday January 11 starting 6:00 a.m. ET.
To register and view the presentation, please click here.
A replay for all conferences will be available on the Events and Presentations section investor section of the Infinity Pharmaceuticals website https://investors.infi.com/events-and-presentations/upcoming-events following the conference.
About Infinity and Eganelisib
Infinity is an innovative biopharmaceutical company dedicated to advancing novel medicines for people with cancer. Infinity is advancing eganelisib, a first-in-class, oral immuno-oncology development candidate that selectively inhibits PI3K-gamma, in multiple clinical studies. MARIO-275 is a global, randomized, placebo-controlled combination study of eganelisib combined with Opdivo® in I/O naïve urothelial cancer. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq® and Abraxane® in front-line TNBC and in combination with Tecentriq and Avastin® in front-line RCC. In collaboration with Arcus Biosciences, Infinity is evaluating a checkpoint inhibitor-free, novel combination regimen of eganelisib plus etrumadenant (dual adenosine receptor antagonist) plus Doxil® in advanced TNBC patients. With these studies Infinity is evaluating eganelisib in the anti-PD-1 refractory, I/O-naïve, and front-line settings. For more information on Infinity, please refer to Infinity's website at www.infi.com.
Opdivo® is a registered trademark of Bristol Myers Squibb.
Tecentriq® is a registered trademark of Genentech, Inc.
Abraxane® is a registered trademark of Abraxis BioScience, LLC.
Avastin® is a registered trademark of Genentech, Inc.
Doxil® is a registered trademark of Baxter Healthcare Corporation.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210107005217/en/
FAQ
When is Infinity Pharmaceuticals' presentation at the J.P. Morgan Healthcare Conference?
What are the dates of the LifeSci Advisors Corporate Access Event for Infinity Pharmaceuticals?
What is eganelisib and how is Infinity Pharmaceuticals developing it?
How can I register for Infinity Pharmaceuticals' investor conference presentations?
What is the stock symbol for Infinity Pharmaceuticals?
